A Phase 1 Study of Allogenic Off-the-Shelf Multi-Tumor-Associated Antigen-Specific T Cell Products (MT-401-OTS) Administered to Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndromes (RAPID)
This study tests a new type of cell therapy called MT-401-OTS for adults with certain blood cancers that have returned or have not fully gone away after past treatments. Researchers want to see if these special immune cells are safe and effective at fighting off the remaining cancer cells.
You might be able to join if you are 65 or older, have specific types of blood cancers like acute myeloid leukemia or myelodysplastic syndrome, and meet certain health and tissue match requirements. People with cancer that has spread to the brain or certain other conditions will not be able to take part.
If you join, you will receive the investigational cell therapy product called MT-401-OTS to see how your body responds to it. Your doctors and the study team will closely monitor your health and safety throughout the process.
This study is currently recruiting participants at medical centers in Duarte, California; Tampa, Florida; and Kansas City, Kansas. It is an early-stage study testing different doses to find the safest and most effective amount.
- 1Tests a novel cell therapy called MT-401-OTS for specific blood cancers.
- 2Open to adults aged 65 and older who meet certain health and match criteria.
- 3Currently recruiting at locations in California, Florida, and Kansas.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.